Mouse anti Human CD2 FITC - CD7 PE
0027
ApplicationsFlow Cytometry
Product group Antibodies
ReactivityHuman
TargetCD2
Overview
- SupplierNordic-MUbio
- Product NameMouse anti Human CD2 FITC - CD7 PE
- Delivery Days Customer7
- Application Supplier NotePBMC: Add10 microl of MAB/10^6 PBMC in 100 microl PBS. Mix gently and incubate for 15 minutes at 2 to 8C. Wash twice with PBS and analyze or fix with 0.5% v/v of paraformaldehyde in PBS and analyze. WHOLE BLOOD: Add10 microl of MAB /100 microl of whole blood. Mix gently and incubate for 15 minutes at room temperature 20C. Lyse the whole blood. Wash once with PBS and analyze or fix with 0.5% v/v of paraformaldehyde in PBS and analyze. See instrument manufacturers instructions for Lysed Whole Blood and Immunofluorescence analysis with a flow cytometer or microscope.
- ApplicationsFlow Cytometry
- Applications SupplierFlow Cytometry
- Category SupplierPrimary antibodies
- CertificationResearch Use Only
- ConjugateFITC, RPE
- Gene ID914
- Target nameCD2
- Target descriptionCD2 molecule
- Target synonymsCD2 antigen (p50), sheep red blood cell receptor; erythrocyte receptor; LFA-2; LFA-3 receptor; lymphocyte-function antigen-2; rosette receptor; SRBC; T11; T-cell surface antigen CD2; T-cell surface antigen T11/Leu-5
- HostMouse
- Protein IDP06729
- Protein NameT-cell surface antigen CD2
- Scientific DescriptionCD2 FITC - CD7 PE
- Shelf life instructionSee expiration date on vial
- ReactivityHuman
- Reactivity SupplierHuman
- Reactivity Supplier NoteCD2=Derived from the hybridization of mouse Sp2/0 myeloma cells with spleen cells from BALB/c mice immunized with t lymphocytes activated by mixed lymphocyte culture. CD7=Derived from the hybridization of mouse P3-X63-Ag8.653 myeloma cells with spleen cells of BALB/c mice immunized with T-acute lymphoblastic leukemia (T-ALL) cells.
- Storage Instruction2°C to 8°C
- UNSPSC12352203
References
- 1.An Improved Rosetting Assay for Detection of Human T Lymphocytes. Kaplan M.E., Clark C., J. Immunol. Methods 1974, 5,131 2.Structural and functional characterization of the CD2 immunoadhesion domain. Evidence for inclusion of CD2 in an alpha-beta protein folding class. Recny M.A., Neidhardt E.A., Sayre P.H., Ciardelli T.L., Reinherz E.L., J. Biol. Chem. 1990 May 2;265(15):85419 3. Partial deletions of the cytoplasm domain of CD2 result in a partial defect in signal transduction. Bierer B.E., Bogart R.E., Burakoff S.J., J. Immunol. 1990 Feb. :144(3):785 4. Functional CD2 mutants unable to bind to, or be stimulated by, LFA-3. Wolff H.L., Burakoff S.J., Bierer B.E., J. Immunol. 1990 Feb. 1;144(4):1215-20 5. Association of CD2 and CD45 on human T lymphocytes. Schraven B., Samstag Y., Altevogt P., Meuer S.C., Nature 1990 May ;345(6270):71-4 6. Isolation and characterization of the genomic human CD7 gene: structural similarity with the murine Thy-1 gene. Schanberg LE, Fleener DE, Kurtzberg J, Haynes BF, Kaufman RE; Proc Natl Acad Sci USA 1991 Jan 1;88(2):603-7 7. Identification of novel B-lineage cells in human fetal bone marrow that coexpress CD7. Grumayer ER, Griesinger F, Hummell DS, Brunning RD, Kersey JH; Blood 1991 Jan ; 77(1):64-8 8. Genuine CD7 expression in acute leukemic and lymphoblastic lymphoma. Osada H, Emi N, Ueda R, Seto M, Koike K, Suchi T, Kojima S, Obata Y, Takahashi T; Leuk Res 1990;14(10):869-77 9. Inhibition of alloresponsive naive and memory T cells by CD7 and CD25 antibodies and by cyclosporine. Akbar An, Amlot PL, Ivory K, Timms A, Janossy G; Transplantation 1990 No;50(5):823-9 10. Comparsion of outcome, clinical, laboratory, and immunological features in 164 children and adults with T-ALL. Garand R, Vannier JP, Bene MC, Faure G, Favre M, Bernard A; Leukemic 1990 No;4(11):739-44